Adaptability of an Undetectable = Untransmissible Model for HBV
NYU Langone Health · with Gilead Sciences · NCT07449091
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–65 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 55
- US sites recruiting
- 1
- Study start
- May 1, 2026
- Record last updated
- May 15, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Persons with chronic hepatitis B (HBV) infection and active viremia are infectious and may transmit virus to others through blood/body fluid exposure. Immune tolerant treatment naive persons with hepatitis B infection express anxiety regarding disclosure of their infection status and significant fear of transmission to their partners leading to social isolation and impact on their personal lives. This study will provide data correlating serum and body fluid viral levels in persons with chronic hepatitis B infection not on therapy and those with viral suppression on long-term anti-retroviral therapy (ART) that may support the concept of "Undetectable=Untransmissible" (U=U) in patients with chronic hepatitis B.
Conditions: Chronic Hepatitis b; Viremia
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
Infected Individuals
- Individuals above 18 years and less than 65 years with chronic hepatitis B infection
- Included according to undermentioned three arms:
- Infected, On-treatment arm: subjects being treated with TAF/TDF for a minimum of 2 years with sustained viral suppression indicating adherence to therapy
- Infected, Untreated control arm: Immune tolerant subjects; 15 with high viral load (>10\^6) and 5 with low viral load (\<10\^6)
- Uninfected Assay Validation controls: 10 subjects with history of prior infection who have convalesced i.e., have lost surface antigen, and developed surface antibody with viral eradication
- Able and willing to provide informed consent
Healthy Controls
- Individuals above 18 years and less than 65 years who have never been infected and have been vaccinated
- Able and willing to provide informed consent
Exclusion Criteria
- Individuals less than 18 years or greater than 65 years of age
- Prior surgery to genitourinary tract, including prior vasectomy
- Prior interferon therapy
- HIV co-infection
- Hepatitis C virus co-infection
- Hepatitis delta virus co-infection
Recruiting US locations
NYU Langone Health
New York, NY 10016
Study contacts (from the official record)
- AnnMarie Liapakis, MD · 212-263-3751 · AnnMarie.Liapakis@nyulangone.org
Similar studies in New York
All healthy volunteers studies in New York →- RecruitingHealthy volunteers
Using Middle School Science Teachers to Address Cancer Health Disparities
Weill Medical College of Cornell University
- Location
- New York, NY + 1 other US site
- Eligibility basics
- Ages 10+
- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- New York, NY + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Staten Island, NY + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Merck Sharp & Dohme LLC
- Location
- East Syracuse, NY + 14 other US sites
- Eligibility basics
- Ages 2 mo–1